Advances in the treatment of endometrial cancer

Journal of the British Menopause Society

Volumn 11, Issue 1, 2005, Pages 18-22

  Oehler, Martin K ^a   Fung, Alison ^a   Jobling, Thomas W ^a  

^a MONASH MEDICAL CENTRE   (Australia)

Author keywords

Endometrial cancer; mTOR; Sentinel lymph node; Trastuzumab; VEGF trap

Indexed keywords

ANASTROZOLE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CAELIX; CISPLATIN; DOXORUBICIN; EPIRUBICIN; EVEROLIMUS; FLUOROURACIL; FULVESTRANT; GESTAGEN; GONADORELIN DERIVATIVE; LETROZOLE; LIPOSOME; MAMMALIAN TARGET OF RAPAMYCIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; PACLITAXEL; RAPAMYCIN; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN TRAP;

ANTINEOPLASTIC ACTIVITY; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; ENDOMETRIUM CANCER; HISTOPATHOLOGY; HUMAN; HYPERTHERMIC THERAPY; HYSTERECTOMY; LAPAROSCOPIC SURGERY; LAPAROTOMY; META ANALYSIS; NONHUMAN; POSTMENOPAUSE; REVIEW; SALPINGOOOPHORECTOMY; SENTINEL LYMPH NODE BIOPSY;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYSTERECTOMY; LAPAROSCOPY; SENTINEL LYMPH NODE BIOPSY;

EID: 15344347076     PISSN: 13621807     EISSN: None     Source Type: Journal    
DOI: 10.1258/1362180053654547     Document Type: Review

References (47)

1. Ries L, Eisner M, Kosary C, et al. SEER Cancer Statistics Review, 1975-2000. Bethesda, MD: NCI, 2003. See http://seer.cancer.gov/csr/1975_2000. Last accessed 10 November 2004
2. Oehler MK, Brand A, Wain GV. Molecular genetics and endometrial cancer. J Br Menopause Soc 2003;9:27-31
3. Franchi M, Ghezzi F, Melpignano M, et al. Clinical value of intra-operative gross examination in endometrial cancer. Gynecol Oncol 2000;76:357-61
4. Quinlivan JA, Petersen RW, Nicklin JL. Accuracy of frozen section for the operative management of endometrial cancer. Br J Obstet Gynaecol 2001;108:798-803
5. Eltabbakh GH. Intraoperative clinical evaluation of lymph nodes in women with gynecologic cancer. Am J Obstet Gynecol 2001; 184:1177-81
6. Ben-Shachar I, Vitellas KM, Cohn DE. The role of MRI in the conservative management of endometrial cancer. Gynecol Oncol 2004;93:233-7
7. Ascher SM, Reinhold C. Imaging of cancer of the endometrium. Radiol Clin North Am 2002;40:563-76
8. Kinkel K, Kaji Y, Yu KK, et al. Radiologic staging in patients with endometrial cancer: a meta-analysis. Radiology 1999;212:711-18
9. Barranger E, Darai E. Lymphatic mapping for gynecologic malignancies. Semin Oncol 2004;31:394-402
10. Raspagliesi F, Ditto A, Kusamura S, et al. Hysteroscopic injection of tracers in sentinel node detection of endometrial cancer: a feasibility study. Am J Obstet Gynecol 2004;191:435-9
11. Niikura H, Okamura C, Utsunomiya H, et al. Sentinel lymph node detection in patients with endometrial cancer. Gynecol Oncol 2004;92:669-74
12. 99mTc colloid and blue dye in patients with endometrial cancer. Tumori 2002; 88:S9-10
13. Barranger E, Cortez A, Grahek D, et al. Laparoscopic sentinel node procedure using a combination of patent blue and radiocolloid in women with endometrial cancer. Ann Surg Oncol 2004; 11:344-9
14. Querleu D, Leblanc E. Laparoscopic surgery for gynaecological oncology. Curr Opin Obstet Gynecol 2003;15:309-14
15. McCartney AJ, Johnson N. Using a vaginal tube to separate the uterus from the vagina during laparoscopic hysterectomy. Obstet Gynecol 1995;85:293-6
16. McCartney AJ, Obermair A. Total laparoscopic hysterectomy with a transvaginal tube. J Am Assoc Gynecol Laparosc 2004; 11 79-82
17. Obermair A, Manolitsas TP, Leung Y, et al. Total laparoscopic hysterectomy for endometrial cancer: patterns of recurrence and survival. Gynecol Oncol 2004;92:789-93
18. Koh WJ, Tran AB, Douglas JG, Stelzer KJ. Radiation therapy in endometrial cancer. Best Pract Res Clin Obstet Gynaecol 2001; 15 417-32
19. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:744-51
20. Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000;355:1404-11
21. Rittenberg PV, Lotocki RJ, Heywood MS, et al. High-risk surgical stage 1 endometrial cancer: outcomes with vault brachytherapy alone. Gynecol Oncol 2003;89:288-94
22. Horowitz NS, Peters WA, 3rd, Smith MR, et al. Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma. Obstet Gynecol 2002;99:235-40
23. Cardenes H, Randall ME. Is observation and salvage (when necessary) an appropriate approach to intermediate risk endometrial cancer? Gynecol Oncol 2003;89:199-200
24. Martin-Hirsch PL, Jarvis G, Kitchener H, Lilford R. Progestagens for endometrial cancer. Cochrane Database Syst Rev 2000: CD001040
25. Ramirez PT, Frumovitz M, Bodurka DC, et al. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol 2004;95:133-8
26. Montz FJ, Bristow RE, Bovicelli A, et al. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol 2002;186:651-7
27. Moore TD, Phillips PH, Nerenstone SR, Cheson BD. Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions. J Clin Oncol 1991;9:1071-88
28. Fiorica JV, Brunetto VL, Hanjani P, et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:10-14
29. Whitney CW, Brunetto VL, Zaino RJ, et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:4-9
30. Addo S, Yates RA, Laight A. A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers. Br J Cancer 2002;87:1354-9
31. Rose PG, Brunetto VL, VanLe L, et al. Phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2000;78 212-16
32. Gallagher CJ, Oliver RT, Oram DH, et al. A new treatment for endometrial cancer with gonadotrophin releasing-hormone analogue. Br J Obstet Gynaecol 1991;98:1037-41
33. Asbury RF, Brunetto VL, Lee RB, et al. Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Am J Clin Oncol 2002;25:557-60
34. Thigpen J, Blessing H, Homesley H, et al. Phase III trial of doxorubicin +/- cisplatin in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group (GOG) study. Proceedings of the American Society for Clinical Oncology 1993;12:261
35. Aapro MS, Van Wijk FH, Bolis G, et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 2003;14:441-8
36. Muggia FM, Blessing JA, Sorosky J, Reid GC. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 2002;20:2360-4
37. Hirai Y, Hasumi K, Onose R, et al. Phase II trial of 3-h infusion of paclitaxel in patients with adenocarcinoma of endometrium: Japanese Multicenter Study Group. Gynecol Oncol 2004;94:471-6
38. Fleming GF, Filiaci VL, Bentley RC, et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol 2004;15:1173-8
39. Ayoub J, Audet-Lapointe P, Methot Y, et al. Efficacy of sequential cyclical hormone therapy in endometrial cancer and the correlation with steroid hormone receptor status. Gynecol Oncol 1988;31:327-37
40. Bafaloukos D, Aravantinos G, Samonis G, et al. Carboplatin, methotrexate and 5-fluorouracil in combination with medroxy-progesterone acetate (JMF-M) in the treatment of advanced or recurrent endometrial carcinoma: a Hellenic cooperative oncology group study. Oncology 1999;56:198-201
41. Rietbroek RC, Schilthuis MS, van der Zee J, Gonzalez D. Hyperthermia in combination with chemotherapy in gynecological cancers. Ned Tijdschr Geneeskd 1999;143:85-8 [Dutch]
42. Piotrkowicz N, Zielinski J, Jonska J, et al. Intracavitary 500 kHz hyperthermia treatment of patients with endometrial and cervical cancer - preliminary clinical and pathological results. Ginekol Pol 2003;74:824-9 [Polish]
43. National Institutes of Health. www.clinicaltrials.gov. Last accessed 10 November 2004
44. Fleming G, Sill M, Thigpen J, et al. Phase II evaluation of trastuzumab in patients with advanced or recurrent endometrial carcinoma: a report on GOG 181B. 39th Meeting of the American Society of Clinical Oncology, 2003: abstract 1821
45. Villella J, Cohen S, Tiersten A, et al. HER2/neu expression in uterine papillary serous cancers. 39th Meeting of the American Society of Clinical Oncology 2003: abstract 1870
46. Carraway H, Hidalgo M. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res 2004;6:219-24
47. Byrne AT, Ross L, Holash J, et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003;9:5721-8